

Informazione Regolamentata n. 20106-17-2025	Data/Ora Inizio Diffusione 2 Aprile 2025 08:00:02	Euronext Star Milan
---	--	---------------------

Societa' : PHARMANUTRA

Identificativo Informazione : 203464
Regolamentata

Utenza - Referente : PHARMANUTRAN04 - Roberto Lacorte

Tipologia : REGEM

Data/Ora Ricezione : 2 Aprile 2025 08:00:02

Data/Ora Inizio Diffusione : 2 Aprile 2025 08:00:02

Oggetto : PHARMANUTRA S.P.A.: NEWS AND
UPDATES ON FOREIGN MARKETS

Testo del comunicato

Vedi allegato

PHARMANUTRA S.P.A.: NEWS AND UPDATES ON FOREIGN MARKETS

FROM TAIWAN TO FINLAND, VIA KUWAIT, AUSTRIA AND MOLDOVA: THE YEAR 2025 STARTS WITH IMPORTANT UPDATES ON THE INTERNATIONAL ACTIVITY WITH EXISTING PARTNERS

Pisa, 2 April 2025 – The Board of Directors of [PharmaNutra S.p.A.](#) (MTA; Ticker PHN), a company specialised in mineral-based nutritional supplements and medical devices for muscles and joints, announces the new goals achieved in the development of its international expansion.

TAIWAN

HONG CHI Biotech, a company of the KSMG Group (Kuang Sheng Medical Group Pharma) that distributes products from SiderAL® and Cetilar® ranges in Taiwan, at the end of last year launched Ultramag®, a food supplement based on Sucrosomial Magnesium®, in the local market, further expanding PharmaNutra's product portfolio in the Asian market.

FINLAND

Following the outstanding successes with Ultramag® and the products of SiderAL® and Cetilar® lines, Sabora Pharma OY, a partner of PharmaNutra S.p.A. since October 2019, last January officially launched UltraCalD3, an exclusive Vitamin D3 formulation with Sucrosomial® Technology, on the Finnish market. Such a product immediately achieved excellent sales in the first month.

KUWAIT

In October 2024, the pharmaceutical company PharmaLife Co. started distributing in Kuwait SiderAL® Forte and SiderAL® Folic, Sucrosomial® iron-based food supplements that are already receiving very positive feedbacks from the market in a territory with high potential.

AUSTRIA

There were also great results on the Austrian market, where PharmaNutra S.p.A. has been present since 2016 thanks to an established partnership with Fresenius Kabi Austria, which has long had products from SiderAL® and Cetilar® ranges in its portfolio. Last year, Fresenius Kabi introduced SiderAL® Med and Apportal®, a complete nutritional supplement developed with the innovative Sucrosomial Technology® and containing as many as 19 nutrients. Both products immediately reported attractive sales performances, in a strategically very important market for PharmaNutra Group companies.

MOLDOVA

Operating for several years in Romania in the distribution of products from SiderAL® and Cetilar® ranges and of Ultramag®, a food supplement based on Sucrosomial Magnesium®, Labormed-Pharma SA, PharmaNutra S.p.A.'s historical partner, has recently added Moldova among the territories in which it distributes the SiderAL® line.

Carlo Volpi, Managing Director of PharmaNutra S.p.A., states: *"In the period between the end of 2024 and the beginning of this year, the Group's international activity reaped the rewards of intensive work and great satisfaction. PharmaNutra's presence abroad is becoming more and more consolidated. Over the coming months, we will be pleased to share with our shareholders and the market some updates related to the definition of new agreements for the distribution of our products on international markets".*

PharmaNutra S.p.A.

Founded and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra is a company established in 2003 that develops unique nutritional supplements and innovative medical devices, taking care of the entire production process. PharmaNutra is a leader in the production of iron-based nutritional supplements under the SiderAL® brand, where it holds important patents on Sucrosomial® Technology, and is considered one of the emerging top players in the medical device sector dedicated to restoring joint capacity thanks to the Cetilar® brand. The latter is now also on the market in the Nutrition version: a line of food supplements designed for those who practice sport frequently. Over the years, the Group - present abroad in 89 countries - has developed a precise strategy in the production of intellectual property, based on the integrated management of all components: proprietary raw materials, patents, trademarks and clinical evidence. PharmaNutra.it

For further details:

PharmaNutra S.p.A.

Via Campodavella, 1 - 56122 Pisa, Italy

Tel. +39 050 7846500

investorrelation@PharmaNutra.it

Internal Press Office

press@calabughi.com

Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan, Italy

Tel. +39 02 83635708

Matteo Russo

mrusso@sprianocommunication.com

Cristina Tronconi

ctronconi@sprianocommunication.com

